Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFFWD.L Regulatory News (FFWD)

  • There is currently no data for FFWD

Completion Placing

12 Feb 2016 17:19

RNS Number : 9963O
FastForward Innovations Limited
12 February 2016
 

12 February 2016

FastForward Innovations Limited

Completion Placing

Admission of New Shares to trading on AIM

Further to its announcements on 28 January and 8 February 2016, the Board of FastForward Innovations Limited ("FastForward" or the "Company") is pleased to announce that it has today completed the placing of 37,426,901 new Ordinary Shares of 1p each (the "Placing Shares") at a price of £0.15 per Placing Share thereby raising US$8,000,000 (£5,614,035 at an exchange rate of £1:US$1.425, being the rate on the date the Company determined the terms of the placing) before expenses (the "Placing").

 

Current Net Asset Value (based on the issued share capital following the Placing)

 

The Company has invested £4.1 million (c. £0.03 per share) into seven investments to date and has, on completion of the Placing, £6.8 million (£0.05 per share) in liquid assets to fund working capital and further investments.

 

Mr. Lorne Abony, the Company's Chief Executive Officer, was pleased to close the Placing in difficult market conditions:

 

"I have had an opportunity to review the current investment portfolio and to work with colleague directors to further develop the Company's future strategy. It is my view, shared by the Board, that the investments made to date have enormous potential for significant shareholder value creation. Beyond this, preliminary analysis indicates that each company is delivering results ahead of their respective business plans and budgets.

 

I intend to provide a comprehensive market update in due course with greater detail around our strategy, specific investment criteria and about our investments and their respective prospects. It is however my goal to work with the Board in the first half of 2016 making opportunistic investments. The second half of 2016 will likely see a heavy emphasis on seeking to crystallize the value of those businesses at valuations well in excess of the value that FFWD acquired its interests; those exits could take the form of investments by third parties at higher valuations, IPO's or sales. I am very comfortable saying that I am truly excited by the management teams we have in place, the milestones that have been achieved, and the results we are seeing, and am very confident that value enhancing events in the near future will reflect positively on our Net Asset Value.

 

The Placing was significantly over subscribed. I appreciate the tremendous confidence shown in me and the rest of the board by new and existing shareholders to deliver them superior returns. Many of our new shareholders are themselves successful technology investors. Their support will further enhance our ability to discover and incubate new tech start ups for the benefit of all our shareholders."

 

Admission of the Placing Shares to AIM

 

The Placing Shares (which will rank pari passu with the existing Ordinary Shares) have been issued and allotted and accordingly, admission to trading on AIM is expected to commence at 8.00 a.m. on 18 February 2016.

 

The enlarged issued share capital of the Company following the issue of the Consideration Shares and the Placing Shares will be 134,108,445 Ordinary Shares with voting rights. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

For further information please visit www.fstfwd.co or contact:

FastForward Innovations Limited Tel: +44 1481 810 100 Elysium Fund Management Limited

Beaumont Cornish Limited (Nomad) Tel: +44 (0) 207 628 3396 James Biddle / Michael Cornish

Peterhouse Corporate Finance Limited (Broker) Tel: +44 (0) 20 7469 0930 Guy Miller / Lucy Williams

 

CAUTIONARY STATEMENT

The AIM Market of London Stock Exchange plc does not accept responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of FastForward Innovations Limited and the companies in which it invests. There can be no assurance that such statements will prove to be accurate, achievable or recognizable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. FastForward Innovations Limited assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCMMGMZNZNGVZM
Date   Source Headline
23rd Jul 20187:00 amRNSAgreement
19th Jul 201812:40 pmRNSFurther investment in Intensity Therapeutics Inc.
9th Jul 201811:17 amRNSIncreased holding in Fralis LLC (Leap Gaming)
6th Jul 20185:44 pmRNSResults for the year ended 31st March 2018
22nd Jun 20182:30 pmRNSInvestment in Vogogo Inc. Conv. Debenture Units
20th Jun 20186:20 pmRNSInvestee Company Update
19th Jun 20187:00 amRNSInvestment in Juvenescence Limited
12th Jun 20187:00 amRNSInvestee Company Update: Subscription into Fralis
11th Jun 20189:53 amRNSSale of Aphria Shares
16th May 20187:00 amRNSRegulatory Approval
23rd Mar 20183:35 pmRNSInvestee Company Update: Nuuvera Inc.
21st Mar 20181:28 pmRNSInvestee Company Update: Nuuvera
12th Mar 20181:00 pmRNSKey Investor Document
7th Mar 20182:34 pmRNSDirector/PDMR Shareholding
7th Mar 20187:00 amRNSProposed Director's Dealing
27th Feb 20183:43 pmRNSInvestee Company Update: Intensity Therapeutics
26th Feb 20184:01 pmRNSInvestee Company Update: Nuuvera
20th Feb 20183:26 pmRNSInvestee Company Update: Nuuvera
13th Feb 201812:22 pmRNSDirector Appointment
13th Feb 201812:05 pmRNSResult of AGM
12th Feb 20184:51 pmRNSTransaction in Own Shares
6th Feb 20189:37 amRNSCorrection of Notice of AGM
2nd Feb 20189:35 amRNSInvestee Company Update: Vemo
31st Jan 201811:04 amRNSTransaction in Own Shares
30th Jan 20185:00 pmRNSNotice of AGM
30th Jan 20184:20 pmRNSNotice of AGM
30th Jan 20188:35 amRNSHolding(s) in Company
29th Jan 20181:33 pmRNSInvestee Company Update: Nuuvera
23rd Jan 20182:43 pmRNSExtension of Share Buy-back Programme
23rd Jan 20181:19 pmRNSTransaction in Own Shares
18th Jan 20183:18 pmRNSInvestment Company Updates: Nuuvera
16th Jan 20183:36 pmRNSInvestee Company Update: Nuuvera
12th Jan 20183:43 pmRNSInvestee Company Update: Nuuvera
12th Jan 20182:23 pmRNSInvestee Company Update: Nuuvera
11th Jan 20188:00 amRNSInvestee Company Update: Nuuvera
8th Jan 20187:00 amRNSInvestee Company Update: Nuuvera
2nd Jan 201811:26 amRNSInvestee Company update: Nuuverra transaction
28th Dec 20173:29 pmRNSHalf-year Report
15th Dec 20179:23 amRNSCompany Secretary Change
15th Dec 20177:00 amRNSInvestee Company Update: Nuuvera
29th Nov 20174:14 pmRNSTransaction in Own Shares
29th Nov 20177:00 amRNSHolding(s) in Company
28th Nov 20174:06 pmRNSTransaction in Own Shares
23rd Nov 201710:12 amRNSHolding(s) in Company
20th Nov 201710:30 amRNSShare Buy-Back Programme
20th Nov 20179:56 amRNSMarket Update
3rd Nov 201712:00 pmRNSInvestee Company Update
9th Oct 20177:00 amRNSUpdate on Nuuverra Investment
18th Sep 20177:00 amRNSDisposal of interest in investee company
15th Aug 20177:00 amRNSInvestee Company Update: Schoold

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.